The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
 
Daniel John Renouf
Honoraria - Amgen; Celgene
Consulting or Advisory Role - Celgene; Shire
Research Funding - Bayer
 
Neesha C. Dhani
Honoraria - Celgene; Sanofi
Consulting or Advisory Role - Celgene; Incyte
 
Petr Kavan
Honoraria - Amgen; Celgene; LEO Pharma
Consulting or Advisory Role - Amgen; Celgene; Novartis; Pfizer; Shire
Travel, Accommodations, Expenses - Amgen; LEO Pharma; Novartis; Pfizer; Roche/Genentech
 
Derek J. Jonker
No Relationships to Disclose
 
Alice Chia-chi Wei
No Relationships to Disclose
 
Tina Hsu
Consulting or Advisory Role - Celgene; Pfizer
 
Patricia A. Tang
Consulting or Advisory Role - AMGEN; Celgene; Genomic Health International; Novartis Canada Pharmaceuticals Inc; Shire
 
Barbara Graham
No Relationships to Disclose
 
Lisa Gallinaro
No Relationships to Disclose
 
Tasnia Hasan
No Relationships to Disclose
 
Weiwei Li
No Relationships to Disclose
 
Kate Hart
No Relationships to Disclose
 
Dongsheng Tu
No Relationships to Disclose
 
Christopher J. O'Callaghan
No Relationships to Disclose